According to Global Genes, more than 350 million people worldwide suffer from rare diseases.

Unfortunately, according to the FDA’s Every Life Foundation, only around 5% of rare diseases have a FDA-approved treatment.

Quintiles, the world’s largest provider of biopharmaceutical development and commercial outsourcing services, has worked on more than 230 rare disease studies since 2010. Here, Laurie Witherwax outlines the patient-centric approach that Quintiles deploys to help pharmaceutical and biotechnology companies get new therapies to patients.